Trial reportCancer science2018
Isolation and molecular analysis of circulating tumor cells from lung cancer patients using a microfluidic chip type cell sorter.
Trial report in Cancer science, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 42 citations in OpenAlex.
- Isolation and molecular analysis of circulating tumor cells from lung cancer patients using a microfluidic chip type cell sorter.Cancer science · 2018Trial
- Hox gene activity directs physical forces to differentially shape chick small and large intestinal epithelia.Developmental cell · 2024Article
- Antitumor activities of a defucosylated anti‑EpCAM monoclonal antibody in colorectal carcinoma xenograft models.International journal of molecular medicine · 2023Article
- The Applications and Challenges of the Development ofCellular and molecular bioengineering · 2023Review
- Cell adhesion molecules and immunotherapy in advanced non-small cell lung cancer: Current process and potential application.Frontiers in oncology · 2023Review
- A Defucosylated Anti-EpCAM Monoclonal Antibody (EpMab-37-mGAntibodies (Basel, Switzerland) · 2022Article
- Biofabrication approaches and regulatory framework of metastatic tumor-on-a-chip models for precision oncology.Medicinal research reviews · 2022Review
- Application of Microfluidics in Detection of Circulating Tumor Cells.Frontiers in bioengineering and biotechnology · 2022Review
- Circulating Tumour Cells (CTCs) in NSCLC: From Prognosis to Therapy Design.Pharmaceutics · 2021Review
- Mesenchymal Characteristics and Predictive Biomarkers on Circulating Tumor Cells for Therapeutic Strategy.Cancers · 2020Review
- Successful selection of mouse sperm with high viability and fertility using microfluidics chip cell sorter.Scientific reports · 2020Article
- A Novel Model of Cancer Drug Resistance: Oncosomal Release of Cytotoxic and Antibody-Based Drugs.Biology · 2020Review
- Detection of AXL expression in circulating tumor cells of lung cancer patients using an automated microcavity array system.Cancer medicine · 2020Article
- Article
- Cell Separations and Sorting.Analytical chemistry · 2020Review
- Viscoelastic microfluidics: progress and challenges.Microsystems & nanoengineering · 2020Review
- Detection of PD-L1 Expression and Its Clinical Significance in Circulating Tumor Cells from Patients with Non-Small-Cell Lung Cancer.Cancer management and research · 2020Article
- Detection of circulating sarcoma tumor cells using a microfluidic chip-type cell sorter.Scientific reports · 2019Article
- Label-free microfluidic sorting of microparticles.APL bioengineering · 2019Review
- The Value of Liquid Biopsies for Guiding Therapy Decisions in Non-small Cell Lung Cancer.Frontiers in oncology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Circulating tumor cells (CTCs) are a tumor-derived material utilized for liquid-based biopsy; however, capturing rare CTCs for further molecular analysis remains technically challenging, especially in non-small-cell lung cancer. Here, we report the results of a clinical evaluation of On-chip Sort, a disposable microfluidic chip-based cell sorter, for capture and molecular analysis of CTCs from patients with lung adenocarcinoma. Peripheral blood was collected from 30 metastatic lung adenocarcinoma patients to enumerate CTCs using both On-chip Sort and CellSearch in a blind manner. Captured cells by On-chip Sort were subjected to further molecular analysis. Peripheral blood samples were also used for detection of EGFR mutations in plasma using droplet digital PCR. Significantly more CTCs were detected by On-chip Sort (22/30; median 5; range, 0-18 cells/5 mL blood) than by CellSearch (9/30; median, 0; range, 0-12 cells/7.5 mL) (P < 0.01). Thirteen of 30 patients who had a negative CTC count by CellSearch had a positive CTC count by On-chip Sort. EGFR mutations in CTCs captured by On-chip Sort were observed in 40.0% (8/20) of patients with EGFR-mutated primary tumor. EGFR mutations were often observed in 53.3% (8/15) of patients detected in plasma DNA. Expressions of EGFR and vimentin protein on CTCs were also successfully assessed using On-chip Sort. These results suggest that On-chip Sort is an efficient method to detect and capture rare CTCs from patients with lung adenocarcinoma that are undetectable with CellSearch. Mutation detection using isolated CTCs remains to be further tackled (UMIN000012488).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.